Proquest Dissertations

Total Page:16

File Type:pdf, Size:1020Kb

Proquest Dissertations NOTE TO USERS This reproduction is the best copy available. UMI* mn u Ottawa L'Universite canadienne Canada's university ITTTT FACULTE DES ETUDES SUPERIEURES L^=l FACULTY OF GRADUATE AND ET POSTDOCTORALES U Ottawa POSTDOCTORAL STUDIES i.'Universiti'; ciimidienne Canada's university Jean-Philippe D'Aoust AUTEUR DE LA THESE / AUTHOR OF THESIS M.Sc. (Neuroscience) GRADE/DEGREE Department of Cellular and Molecular Medicine 'FACULTETCOLETDEPA!™ Identifying the Roles of the Amino Terminal and first Transmembrane Regions of Human Dl-like Dopaminergic Receptors Using Mutagenesis TITRE DE LA THESE / TITLE OF THESIS M. Tiberi DIRECTEUR (DIRECTRICE) DE LA THESE / THESIS SUPERVISOR CO-DIRECTEUR (CO-DIRECTRICE) DE LA THESE / THESIS CO-SUPERVISOR EXAMINATEURS (EXAMINATRICES) DE LA THESE/THESIS EXAMINERS P. Albert J. Da Silva Gary W. Slater Le Doyen de la Faculte des etudes superieures et postdoctorales / Dean of the Faculty of Graduate and Postdoctoral Studies IDENTIFYING THE ROLES OF THE AMINO TERMINAL AND FIRST TRANSMEMBRANE REGIONS OF HUMAN DL-LIKE DOPAMINERGIC RECEPTORS USING MUTAGENESIS by JEAN-PHILIPPE D'AOUST This thesis is submitted as a partial fulfillment of the M.Sc. program in Neuroscience June 2009 Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa © Jean-Philippe D'Aoust, Ottawa, Ontario, Canada, June 2009 Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de Pedition 395 Wellington Street 395, rue Wellington Ottawa ON MAOISM OttawaONK1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-59466-7 Our file Notre reference ISBN: 978-0-494-59466-7 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lntemet, preter, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in this et des droits moraux qui protege cette these. Ni thesis. Neither the thesis nor la these ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent etre imprimes ou autrement printed or otherwise reproduced reproduits sans son autorisation. without the author's permission. In compliance with the Canadian Conformement a la loi canadienne sur la Privacy Act some supporting forms protection de la vie privee, quelques may have been removed from this formulaires secondaires ont ete enleves de thesis. cette these. While these forms may be included Bien que ces formulaires aient inclus dans in the document page count, their la pagination, il n'y aura aucun contenu removal does not represent any loss manquant. of content from the thesis. ••• Canada Abstract Although Dl-like dopaminergic receptors (D1R and D5R) share similar primary sequences, they possess distinct ligand binding and G protein-coupling properties. Since no ligands discriminate the closely related D1R and D5R, the discovery of their subtype- specific functional and physiological functions is stalled. To provide additional conformational data about the binding pocket of Dl-like receptors, we assessed the functional roles of their highly divergent amino terminal cassette. Using a chimerical approach, we swapped the extracellular amino terminal (NT) and first transmembrane (TM1) regions of human Dl-like receptors and found that both regions distinctly control dopamine efficacy. Furthermore, chimeras with a swapped TM1 domain have altered affinity and selectivity properties. We further identified two residues in TM1 controlling ligand binding while one of them is also crucial for dopamine efficacy. Our present results highlight structural and functional roles of TM1 and NT of human Dl-like dopaminergic receptors. u Table of contents ABSTRACT II TABLE OF CONTENTS Ill LIST OF TABLES V CHAPTER 2. MANUSCRIPT #1 v CHAPTER 3. MANUSCRIPT #2 v LIST OF FIGURES VI CHAPTER 1. INTRODUCTION vi CHAPTER 2. MANUSCRIPT #1 vi CHAPTER 3. MANUSCRIPT #2 vn CHAPTER 4. GENERAL DISCUSSION vm CHAPTER 6. APPENDICES vm LIST OF ABBREVIATIONS IX ACKNOWLEDGMENTS XII CHAPTER 1. INTRODUCTION 1 1.1 THE BASIC PRINCIPLES OF DOPAMINE NEUROTRANSMISSION 2 1.1.1 Neurotransmitter synthesis, storage and release 2 1.1.2 The family of dopamine receptors 3 1.1.3 The nigrostriatal pathway and Parkinson's disease 7 1.1.4 The mesocortical and mesolimbic pathways and schizophrenia 9 1.1.5 The hypothalamo-pituitary pathway 10 1.1.6 Roles of dopamine outside the central nervous system 11 1.2 CRYSTALLOGRAPHIC STUDIES OF G PROTEIN-COUPLED RECEPTORS 12 1.2.1 Rhodopsin, the first crystallized GPCR 12 1.2.2 Problems with the crystallization other GPCRs and their resolution 15 1.2.3 Differences between the new three-dimensional structures of mutant GPCRs and rhodopsin 17 1.3 REGULATION OF G PROTEIN-COUPLED RECEPTOR FUNCTIONS 19 1.3.1 Families of G protein-coupled receptors under the GRAFS system 19 1.3.2 The heterotrimeric G proteins and their effectors 21 1.3.3 Receptor trafficking, from the endoplasmic reticulum to lysosomes 27 1.4 THE DOPAMINE Dl-LIKE RECEPTOR SUB-FAMILY 32 1.4.1 Polymorphisms occurring in Dl-like receptors 32 1.4.2 Characteristics of the Dl-like receptor sub-family 33 1.4.3 The distribution of Dl-like dopamine receptors, in brain and in periphery... 37 1.4.4 What have we learned from Dl-like receptor knockout mice models? 40 1.4.5 The binding pocket of dopamine Dl receptor 43 1.4.6 Elucidating the functional properties of structural components of Dl-like receptors 45 1.5 ISSUES, HYPOTHESES AND OBJECTIVES 48 iii CHAPTER 2. MANUSCRIPT #1 51 CHAPTER 3. MANUSCRIPT #2 97 CHAPTER 4. GENERAL DISCUSSION 142 4.1 THE AMINO TERMINAL CASSETTE OF D1-LIKE RECEPTORS 143 4.2 CHEMICAL STRUCTURES AND RECEPTOR ACTIVATION: IS THERE A LINK? 144 4.3 COOPERATION OF RESIDUES WITHIN THE TM1 HELIX 148 4.4 SEQUENTIAL BINDING OF LIGANDS 151 4.5 A POSSIBLE CHOLESTEROL BINDING RESIDUE 153 4.6 UNSOLVED QUESTIONS 155 4.7 CLOSING REMARKS 156 CHAPTER 5. REFERENCES 158 CHAPTER 6. APPENDICES 177 iv List of tables Chapter 2. Manuscript #1 Table I. Dissociation constants (Kd) and maximal binding capacity (Bmax) values of N- [methyl-3H]-SCH23390 for wild type and chimerical Dl-like receptors 64 Table II. Inhibitory dissociation constants (Kj) values of dopaminergic ligands for wild type and chimerical Dl-like receptors 67 Table III. Inhibitory dissociation constants (Kj) values of dopaminergic ligands for wild type and TM1-swapped Dl-like receptors 71 Table SI. List of custom PCR primers 93 Chapter 3. Manuscript #2 Table I. Dissociation constants (Kd) and maximal binding capacity (Bmax) values of N- [methyl-3H]-SCH23390 for wild type and multiple point mutant Dl-like receptors Ill Table II. Inhibitory dissociation constants (Kj) values of dopamine and benzazepine ligands for wild type and multiple point mutant Dl-like receptors 113 Table III. Inhibitory dissociation constants (Kj) values of antipsychotic drug for wild type and multiple point mutant Dl-like receptors 114 Table IV. Dissociation constants (Kd) and maximal binding capacity (Bmax) values of N- [methyl-3H]-SCH23390 for wild type and single point mutant Dl-like receptors 117 Table V. Inhibitory dissociation constants (Kj) values of dopaminergic ligands for wild type and single point mutant Dl-like receptors 119 Table SI. List of custom PCR primers 138 v List of figures Chapter 1. Introduction Figure I. Synthesis, storage, release and reuptake of dopamine 4 Figure II. Schematic representation of a G protein-coupled receptor 6 Figure III. Three-dimensional structure of rhodopsin, a GPCR 14 Figure IV. Activation and signal termination of heterotrimeric G proteins 22 Figure V. The cAMP-PKA signaling pathway 24 Figure VI. Trafficking of G protein-coupled receptors following activation 30 Figure VII. Topology of human Dl-like dopaminergic receptors 34 Figure VIII. DARPP-32 signaling cascade 36 Chapter 2. Manuscript #1 Figure 1. Primary sequence of the extracellular amino terminus (NT) and first transmembrane domain (TM1) of the human Dl-like receptors and schematic representation of wild type and chimerical receptors 63 Figure 2. Affinity change (in %) of dopaminergic ligands for chimerical receptors relative to parent wild type receptor 68 Figure 3. Selectivity ratios of dopaminergic ligands for wild type and chimerical Dl-like receptors 70 Figure 4. Affinity change (in %) of dopaminergic ligands for TM1-swapped receptors relative to parent wild type receptor 72 vi Figure 5. Selectivity ratios of dopaminergic ligands for wild type and TM1 -swapped Dl- like receptors 73 Figure 6. Agonist-independent activity of wild type and chimerical Dl-like receptors expressed in HEK293 cells 76 Figure 7. DA-mediated stimulation of adenylyl cyclase activity by wild type and chimerical Dl-like receptors expressed in HEK293 cells 77 Figure 8. Basal activity of antipsychotics on HEK293 cells expressing wild type or TM1- swapped Dl-like receptors 79 Figure 9. Activity of dopaminergic agonists on HEK293 cells expressing wild type or TMl-swapped Dl-like receptors 82 Figure SI. Chemical structures of dopamine and benzazepine ligands 95 Figure S2. Chemical structures of antipsychotic drugs 96 Chapter 3. Manuscript #2 Figure 1. Primary sequence of the first transmembrane domain (TM1) of human Dl-like receptors and schematic representation of wild type and mutant receptors 110 Figure 2. Affinity change (in %) of dopaminergic ligands for multiple point mutant receptors relative to parent wild type receptor 115 Figure 3.
Recommended publications
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC
    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
    [Show full text]
  • In Search of a Generic Chiral Strategy: 101 Separations with One Method
    32 September 2009 In Search of a Generic Chiral Strategy: 101 Separations With One Method Jim Thorn and John C. Hudson, Beckman Coulter, Inc., Fullerton, CA, USA In any approach to drug discovery, the challenges presented to the analytical chemist are compounded when a product contains one or more chiral centres. Enantiomers are stereoisomers that display chirality, having one or more asymmetric carbon centres, allowing them to exist as non-superimposable mirror images of one another. These isomers are difficult to analyze as they are both physically and chemically identical and differ only in the way they bend plane-polarized light and in their behaviour in a chiral environment. The key to separating enantiomers is to first enantiomeric drug substances. A group of Boniface Hospital, Winnipeg, MB, Canada. create diastereomers from these compounds selected from a set of drugs Solutions of these drug and metabolite enantiomers. Diastereomers may be and metabolites of pharmaceutical and standards were purchased or prepared at a created through chemical derivatization forensic interest was separated using concentration of 1mg/mL and diluted to with a “chiral” reagent, or they may be HSCDs. This was a challenging group 25ppm (25ng/ µL) in water. formed transiently through interactions with because it included many closely related Reference Marker: 1,3,6,8- chiral selectors. The latter, of course, is metabolites of drug substances, in addition Pyrenetetrasulfonate (PTS), 10mM in water: usually the most desirable as it is the easiest to the parent drugs. For simplicity, the 2µL added to each sample. to employ. These chiral selectors have screening strategy was designed to historically been introduced in the form of separate the enantiomers of individual Instrument: P/ACE™ MDQ Capillary chromatographic media using HPLC, SFC or compounds, although we present Electrophoresis System (Beckman Coulter, GC as the separation technique.
    [Show full text]
  • Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity
    pharmaceuticals Article Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity Michele Tonelli 1,* , Anna Sparatore 2,* , Nicoletta Basilico 3,* , Loredana Cavicchini 3, Silvia Parapini 4 , Bruno Tasso 1 , Erik Laurini 5 , Sabrina Pricl 5,6 , Vito Boido 1 and Fabio Sparatore 1 1 Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV, 3, 16132 Genova, Italy; [email protected] (B.T.); [email protected] (V.B.); [email protected] (F.S.) 2 Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy 3 Dipartimento di Scienze Biomediche Chirurgiche e Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milano, Italy; [email protected] 4 Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milano, Italy; [email protected] 5 Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, Piazzale Europa 1, 34127 Trieste, Italy; [email protected] (E.L.); [email protected] (S.P.) 6 Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland * Correspondence: [email protected] (M.T.); [email protected] (A.S.); [email protected] (N.B.) Received: 4 October 2020; Accepted: 21 October 2020; Published: 25 October 2020 Abstract: Leishmaniases are neglected diseases that are endemic in many tropical and sub-tropical Countries. Therapy is based on different classes of drugs which are burdened by severe side effects, occurrence of resistance and high costs, thereby creating the need for more efficacious, safer and inexpensive drugs.
    [Show full text]
  • N-Alkylamino Derivates of Aromatic, Tricyclic Compounds in the Treatment of Drug-Resistant Protozoal Infections
    Europaisches Patentamt 0 338 532 European Patent Office Qv Publication number: A2 Office europeen des brevets EUROPEAN PATENT APPLICATION 31/54 © Application number: 89107027.8 © mt.ci.4.A61K 31/38 , A61K @ Date of filing: 19.04.89 © Priority: 20.04.88 US 183858 © Applicant: MERRELL DOW 12.09.88 US 243524 PHARMACEUTICALS INC. 2110 East Galbraith Road @. Date of publication of application: Cincinnati Ohio 45215-6300(US) 25.10.89 Bulletin 89/43 © Inventor: Bitonti, Alan J. © Designated Contracting States: 7854 Carraway Court AT BE CH DE ES FR GB GR IT LI LU NL SE Maineville Ohio 45039(US) Inventor: McCann, Peter P. 3782 Cooper Road Cincinnati Ohio 45241 (US) Inventor: Sjoerdsma, Albert 5475 Waring Drive Cincinnati Ohio 45243(US) © Representative: Vossius & Partner Siebertstrasse 4 P.O. Box 86 07 67 D-8000 Munchen 86(DE) © N-alkylamino derivates of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections. © Drug-resistant protozoal infection, particularly, drug-resistant malarial infection in humans, can be effectively treated with standard antiprotozoal agents if administered in conjunction with a tricyclic N-aminoalkyi iminodiben- zyl, dibenzylcycloheptane and cycloheptene, phenothiazine, dibenzoxazepine, dibenzoxepine, or thioxanthene derivative. CM < CM CO in oo CO CO LU Xerox Copy Centre EP 0 338 532 A2 N-ALKYLAMINO DERIVATIVES OF AROMATIC, TRICYCLIC COMPOUNDS IN THE TREATMENT OF DRUG- RESISTANT PROTOZOAL INFECTIONS This invention relates to the use of certain N-(aminoalkyl) derivatives of iminodibenzyl, dibenzyl- cycioheptane and cycloheptene, phenothiazine, dibenzoxazepine, dibenzoxepine, and thioxanthene in the treatment of drug-resistant malaria and in the treatment of other drug-resistant protozoal infections.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • United States Patent Office Patented June 10, 1969
    3,449,427 United States Patent Office Patented June 10, 1969 2 l optical isomers. Unless otherwise specified in the descrip 3,449,427 AMINOCYCLOPROPANE DERVATIVES OF tion and accompanying claims, it is intended to include all 5H-DIBENZOadCYCLOHEPTENES isomers, whether separated or mixtures thereof. Carl Kaiser, Haddon Heights, N.J., and Charles L. Zirkle, The novel aminocyclopropane derivatives of 5H-di Berwin, Pa., assignors to Smith Kline & French Labora benzoadcycloheptenes of this invention are prepared tories, Philadelphia, Pa., a corporation of Pennsylvania by several methods, the choice of which depending on the No Drawing. Filed June 3, 1965, Ser. No. 461,176 definitions of m, n, R1 and R2. The starting materials for Int. CI. C07c87/28, 91/16, 149/42 these methods are generally 5H-dibenzo(a,d)cyclohep U.S. C. 260-570.8 8 Claims tenes having the formula: O ABSTRACT OF THE DISCLOSURE Y\ 5[2-(N-N di substituted amino) cyclopropyl)-10,11-di R hydro 5H dibenzo(a,d)cycloheptanes are prepared via the amides and acids. The compounds are antidepressants, 5 X transquillizers and anorectics. H Formula II This invention relates to novel aminocyclopropane de in which Y and R are as defined in Formula I. These rivatives of 5H-dibenzoadcycloheptenes having useful 20 compounds are prepared by reduction of the correspond pharmacodynamic activity. More specifically, the com ing 5H-dibenzo(a,d)cyclohepten-5-ones with, for example, pounds of this invention have central nervous system sodium in a lower alkanol, preferably, ethanol or by the activity such as antidepressant, tranquilizing and anorectic Wolff-Kishner method.
    [Show full text]
  • University of Groningen Chiroptical Molecular Switches De Lange
    University of Groningen Chiroptical molecular switches de Lange, Ben IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2006 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): de Lange, B. (2006). Chiroptical molecular switches: synthesis and applications. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 26-09-2021 CHAPTER 5 NON-CHIRQL STERICALLY OVERCROWDED ALKENES Temperature dependent NMR measurements have been successfully applied to obtain thermal isomerization barriers of chiral sterically overcrowded bistricyclic ethylenes functionalized with different bridging groups in the lower and upper part, which could not be resolved into their enantiomers via HPLC, as shown in the
    [Show full text]
  • Sodium Channel Na Channels;Na+ Channels
    Sodium Channel Na channels;Na+ channels Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na +) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential. www.MedChemExpress.com 1 Sodium Channel Inhibitors & Modulators (+)-Kavain (-)-Sparteine sulfate pentahydrate Cat. No.: HY-B1671 ((-)-Lupinidine (sulfate pentahydrate)) Cat. No.: HY-B1304 Bioactivity: (+)-Kavain, a main kavalactone extracted from Piper Bioactivity: (-)-Sparteine sulfate pentahydrate ((-)-Lupinidine sulfate methysticum, has anticonvulsive properties, attenuating pentahydrate) is a class 1a antiarrhythmic agent and a sodium vascular smooth muscle contraction through interactions with channel blocker. It is an alkaloid, can chelate the bivalents voltage-dependent Na + and Ca 2+ channels [1]. (+)-Kav… calcium and magnesium. Purity: 99.98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg 50 mg A-803467 Ajmaline Cat. No.: HY-11079 (Cardiorythmine; (+)-Ajmaline) Cat. No.: HY-B1167 Bioactivity: A 803467 is a selective Nav1.8 sodium channel blocker with an Bioactivity: Ajmaline is an alkaloid that is class Ia antiarrhythmic agent.
    [Show full text]
  • Trimeprazine Increases IRS2 in Human Islets and Promotes Pancreatic Β Cell Growth and Function in Mice
    Trimeprazine increases IRS2 in human islets and promotes pancreatic β cell growth and function in mice Alexandra Kuznetsova, … , Arun Sharma, Morris F. White JCI Insight. 2016;1(3):e80749. https://doi.org/10.1172/jci.insight.80749. Research Article Endocrinology Metabolism The capacity of pancreatic β cells to maintain glucose homeostasis during chronic physiologic and immunologic stress is important for cellular and metabolic homeostasis. Insulin receptor substrate 2 (IRS2) is a regulated adapter protein that links the insulin and IGF1 receptors to downstream signaling cascades. Since strategies to maintain or increase IRS2 expression can promote β cell growth, function, and survival, we conducted a screen to find small molecules that can increase IRS2 mRNA in isolated human pancreatic islets. We identified 77 compounds, including 15 that contained a tricyclic core. To establish the efficacy of our approach, one of the tricyclic compounds, trimeprazine tartrate, was investigated in isolated human islets and in mouse models. Trimeprazine is a first-generation antihistamine that acts as a partial agonist against the histamine H1 receptor (H1R) and other GPCRs, some of which are expressed on human islets. Trimeprazine promoted CREB phosphorylation and increased the concentration of IRS2 in islets. IRS2 was required for trimeprazine to increase nuclear Pdx1, islet mass, β cell replication and function, and glucose tolerance in mice. Moreover, trimeprazine synergized with anti-CD3 Abs to reduce the progression of diabetes in NOD mice. Finally, it increased the function of human islet transplants in streptozotocin-induced (STZ-induced) diabetic mice. Thus, trimeprazine, its analogs, or possibly other compounds that increase IRS2 in islets and β cells without […] Find the latest version: https://jci.me/80749/pdf RESEARCH ARTICLE Trimeprazine increases IRS2 in human islets and promotes pancreatic β cell growth and function in mice Alexandra Kuznetsova,1 Yue Yu,1 Jennifer Hollister-Lock,2 Lynn Opare-Addo,1 Aldo Rozzo,1 Marianna Sadagurski,1 Lisa Norquay,1 Jessica E.
    [Show full text]
  • United States Patent Office Patented Aug
    3,524,000 United States Patent Office Patented Aug. 11, 1970 2 3,524,000 pounds with the substantial absence of significant toxic ANTHELMINTC COMPOSITIONS AND effects. Still another object is to provide a method for METHOD OF USING SAME treating helminthiasis with tricyclic compounds together John R. Egerton, Neshanic Station, and Joseph Di Netta, With anthelmintically active 2-substituted benzimidazoles Watchung, N.J., assignors to Merck & Co., Inc., Rah wherein the tricyclic compounds enhance the activity of way, N.J., a corporation of New Jersey the benzimidazoles. These and other objects will appear No Drawing. Continuation-in-part of application Ser. No. from the detailed description which follows. 439,926, Mar. 15, 1965. This application Oct. 20, 1967, According to the present invention, it has been sur Ser. No. 676,697 Int, C.A01n 9/22 A61d 7/00 A61k27/00 prisingly discovered that the anthelmintic activity of 2-sub O stituted benzimidazoles can be greatly enhanced when the U.S. C. 424-267 13 Claims benzimidazole is administered to the host animal in the presence of certain classes of tricyclic compounds. Thus, in one of its preferred aspects, the invention provides ABSTRACT OF THE DISCLOSURE novel 2-component compositions wherein one component The anthelmintic activity of 2-substituted benzimida is at least one of certain tricyclic compounds and the zoles is greatly enhanced when the benzimidazole is ad other component is at least one anthelmintically active ministered to the host animal in the presence of a tricyclic 2-substituted benzimidazole. The 2-substituted benzimida compound selected from the group consisting of dibenzo - Zoles contemplated for use in the present invention have cycloheptenes and thioxanthenes.
    [Show full text]
  • 9: Analytical Standards
    CATALOGUE NUMBER 9 ANALYTICAL STANDARDS Table of Contents Standards for Special Applications 3 Standards for Routine Analytical Applications 82 Certified Primary Pharmaceutical Standards 3 Environmental Standards 82 Certified GMO Materials 31 Particle Size Standards 115 Certified Clinical Chemistry Standards 33 Conductivity Standards 116 Other Certified Standards 34 Ion Chromatography Standards 116 Custom & OEM Standards 44 Redox Standards 117 Certified Industrial Raw Materials 44 Forensic & Veterinary Standards 117 Certified Drugs, Metabolites, & Impurities 45 Polymer Standards 126 Certified Food & Agriculture Standards 58 Petrochemical Standards 127 Proficiency Testing for Environmental Analysis 60 AAS/ICP Standards 130 Chromatography & CE Test Mixes 131 Selected Certified Reference Materials 64 TOC Standards 132 Environmental Standards 64 Melting Point Standards 132 Trace Cert Organics 75 Spectroscopy Standards—TraceCert 132 Occupational Hygiene Standards 76 MS Markers 134 Secondary Pharma Standards 76 Pharmaceutical & Clinical Standards 134 Titrimetric Substances 81 X-Ray Standards 135 Certified Spectroscopy Standards 81 Food & Beverage Standards 135 Gravimetry Standards 147 NMR Standards 147 Color Reference Solutions 148 Miscellaneous 148 NOTE: This publication is designed for electronic use only. Hazard and Safety information can be found on product detail pages and at sigma-aldrich.com/safetycenter. 2 Analytical Standards Technical Support: [email protected] Standards for Special Applications Certified Primary Pharmaceutical
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,897,788 B2 Fecher Et Al
    US007897788B2 (12) United States Patent (10) Patent No.: US 7,897,788 B2 Fecher et al. (45) Date of Patent: Mar. 1, 2011 (54) INDOL-1-YL-ACETIC ACID DERIVATIVES OTHER PUBLICATIONS Chemical Abstracts Registry No. 347911-97-1, entry date into the (75) Inventors: Anja Fecher, Basel (CH); Heinz Fretz, Registry file on STN is Jul 24, 2001.* Riehen (CH); Kurt Hilpert, Hofstetten Souillac, et al., Characterization of Delivery Systems, Differential (CH); Markus Riederer, Liestal (CH) Scanning Calorimetry in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227.* (73) Assignee: Actelion Pharmaceutical Ltd., Vippagunta et al. (Advanced Drug Delivery Reviews, 48 (2001), pp. Allschwil (CH) 3-26. Doan et al., Journal of Clinical Pharmacology, 2005, 45, pp. 751 (*) Notice: Subject to any disclaimer, the term of this 762.* patent is extended or adjusted under 35 Barnes et al., European Respiratory Journal, 2005, 25, pp. 1084 U.S.C. 154(b) by 1196 days. 1105.* Philip L. Gould. International Journal of Pharmaceutics, vol. 33, pp. (21) Appl. No.: 10/598,781 201-217 (1986). Warawa et al., J. Med. Chem... vol. 44, pp. 372-389 (2001). (22) PCT Filed: Mar. 8, 2005 Gastpar et al., J. Med. Chem... vol. 41, pp. 4965-4972 (1998). Richard C. Larocket al., "Comprehensive Organic Transformations: (86). PCT No.: PCT/EP2OOS/OO2418 A Guide to Functional Group Preparations'. Wiley-VCH publishers, Second Edition (1999). S371 (c)(1), Berge et al., Journal of Pharmaceutical Sciences, vol. 66, pp. 1-19 (2), (4) Date: Sep. 11, 2006 (1977). Sawyer et al., British Journal of Pharmacology, vol.
    [Show full text]